National Institute on Drug Abuse; Notice of Closed Meetings, 49388-49389 [2017-23128]
Download as PDF
<![CDATA[
49388
Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Career Development in
Environmental Research.
Date: November 2, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIEHS/National Institutes of Health
Keystone Building, 530 Davis Drive, Research
Triangle Park, NC 27709 (Virtual Meeting).
Contact Person: Laura A. Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, National Institute of Environmental
Health Sciences, Research Triangle Park, NC
27709, 919–541–2824, laura.thomas@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: October 20, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–23180 Filed 10–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health.
Notice.
AGENCY:
sradovich on DSK3GMQ082PROD with NOTICES
[FR Doc. 2017–23178 Filed 10–24–17; 8:45 am]
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by emailing the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive
SUMMARY:
VerDate Sep<11>2014
22:06 Oct 24, 2017
Jkt 244001
Segmented Metallic Guidewires
Description of Technology: The
invention pertains to segmented
metallic guidewires that are suitable for
MRI catheterization. Guidewires contain
plurality of short conductive metallic
segments that are individually short
enough to not resonate during MR
imaging. The conductive segments are
electrically insulated from each other
and mechanically coupled together endto-end via connectors, such as stiffness
matched connectors, to provide a
sufficiently long, strong, and flexible
guidewire for catheterization that is
non-resonant during MRI.
Potential Commercial Applications:
Endovascular interventions.
Inventors: Robert Lederman, Ozgur
Kocaturk, Burcu Basar (NHLBI).
Intellectual Property: HHS Reference
No. E–253–2014/0, U.S. Provisional
Patent Application 61/066,167 filed
October 20, 2014, International Patent
Application PCT/US2015/056266 filed
October 19, 2015, European Patent
Application 15787824.0 October 19,
2015 and U.S. Patent Application 15/
514,744 filed March 27, 2017.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@nih.gov.
Dated: October 18, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
Government-Owned Inventions;
Availability for Licensing
ACTION:
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing. A description of the
technology follows.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; R01/F31/
K01/K99 Conflicts.
Date: December 1, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Library of Medicine/Center
for Scientific Review, 6701 Rockledge Drive,
Room 3042, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Zoe E. Huang, MD,
Scientific Review Officer, Division of
Extramural Programs, National Library of
Medicine, NIH, 6705 Rockledge Drive, Suite
301, Bethesda, MD 20892–7968, 301–594–
4937, huangz@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: October 19, 2017.
Michelle Trout,
Program Analyst, Office of the Federal
Advisory Committee Policy.
[FR Doc. 2017–23129 Filed 10–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Multi-
E:\FR\FM\25OCN1.SGM
25OCN1
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices
Site Studies for System-Level
Implementation of Substance Use Prevention
and Treatment Services (R01; R34).
Date: November 7, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Limited
Competition—Cohort Studies of HIV/AIDS
and Substance Abuse (U01).
Date: November 7, 2017.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Exceptional Research on HIV/
AIDS and Substance Abuse (R01).
Date: November 10, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Wearable to Track Recovery and Relapse
Factors for People w/Addiction (R43, R44).
Date: November 21, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
VerDate Sep<11>2014
22:06 Oct 24, 2017
Jkt 244001
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: December 4, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Nasal
Delivery of CNS Therapeutics (R41, R42, R43,
R44).
Date: December 5, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Conference Grant Review (R13).
Date: December 6, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Shang-Yi Anne Tsai,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, shangyi.tsai@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–23128 Filed 10–24–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
49389
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Amy Petrik, 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Neutralizing Antibodies to Influenza
HA and Their Use and Identification
Description of Technology: The
effectiveness of current influenza
vaccines varies by strain and season, in
part because influenza viruses
continuously evolve to evade human
immune responses. While the majority
of seasonal influenza infections cause
relatively mild symptoms, each year
influenza virus infections result in over
500,000 hospitalizations in the United
States and Europe. Current standard of
care for individuals hospitalized with
uncomplicated influenza infection is
administration of neuraminidase
inhibitors. However, frequent use of
such antiviral drugs increases the risk
that the virus will develop drug
resistance, especially in high-risk
populations. Thus, alternative strategies
are required to protect or treat
vulnerable populations who have been
hospitalized with severe influenza.
Using a combination of recombinant
proteins and sophisticated flow
cytometry, scientists at NIAID isolated
families of antibodies capable of
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49388-49389]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23128]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Multi-
[[Page 49389]]
Site Studies for System-Level Implementation of Substance Use
Prevention and Treatment Services (R01; R34).
Date: November 7, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Limited Competition--Cohort Studies of HIV/AIDS and
Substance Abuse (U01).
Date: November 7, 2017.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Advancing Exceptional Research on HIV/AIDS and
Substance Abuse (R01).
Date: November 10, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Wearable to Track Recovery and Relapse Factors for
People w/Addiction (R43, R44).
Date: November 21, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: December 4, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892-9550, 301-827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Nasal Delivery of CNS Therapeutics (R41, R42, R43,
R44).
Date: December 5, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892,
301-827-5840, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Conference Grant Review (R13).
Date: December 6, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: October 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-23128 Filed 10-24-17; 8:45 am]
BILLING CODE 4140-01-P
